NEW YORK ( TheStreet) -- CHANGE IN RATINGS
(AINV - Get Report)
was initiated with a buy rating at UBS. $10 price target. Still a cut above other BDCs, UBS said.
was initiated with a neutral rating at Citigroup. $60 price target. Valuation call, as the stock is already up 35% year to date, Citi said.
was initiated with a neutral rating at Nomura. Valuation call, based on an $85 price target, Nomura said.
(EBAY - Get Report)
was initiated with an outperform rating at BMO Capital. $64 price target. Company should continue to deliver solid growth, BMO said.
was upgraded at BMO Capital from market perform to outperform. $56 price target. Company is seeing higher rates and cutting CapEx spending, BMO Capital said.
was upgraded to hold at TheStreet Ratings.
(GRPN - Get Report)
was downgraded at Wells Fargo to market perform. Company's business model is changing for the worse, Wells Fargo said.
Groupon was downgraded to underperform at Bank of America/Merrill Lynch. $4.20 price target. Company is realizing lower margins, BofA/Merrill said.
was downgraded at Bank of America/Merrill said. $47 price target. Estimates also cut, as the company is seeing lower margins, BofA/Merrill said.
was downgraded at Jefferies from buy to hold. $59 price target. Management cut its volume guidance, Jefferies said.
(RVBD - Get Report)
was downgraded at Sterne Agee from buy to neutral. CFO is stepping down, which adds risk to the model, Sterne Agee said.
was downgraded at Williams Capital from outperform to perform. Valuation call, based on a $160 price target, Williams said.
was downgraded to hold at TheStreet Ratings.
was downgraded at Morgan Stanley from equal-weight to underweight. $10 price target. Company is seeing higher operating costs, Morgan Stanley said.
(VMW - Get Report)
was initiated with a hold rating at Stifel Nicolaus. 2013 will likely be a transition year for the company, Stifel Nicolaus said.
was downgraded at Bank of America/Merrill Lynch. $55 price target. Company may be facing increased competition, BofA/Merrill said.
was downgraded at UBS to neutral from buy. $51 price target. Disappointing capex, UBS said.